COST OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) IN SECOND-LINE (2L) ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): MATCH ADJUSTED INDIRECT COMPARISON (MAIC) OF NIVOLUMAB AND REGORAFENIB

被引：2
|
作者：
Venkatachalam, M. [1 ]
Stenehjem, D. [2 ]
Parikh, N. D. [3 ]
Singh, P. [4 ]
Marett, B. [4 ]
Sill, B. [4 ]
Wisniewski, T. [4 ]
Prakash, V [5 ]
Shukla, P. [5 ]
Korytowsky, B. [4 ]
Siddiqui, M. K. [5 ]
机构：
[1] PAREXEL Int, Waltham, MA USA
[2] Univ Minnesota, Duluth, MN 55812 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] PAREXEL Int, Chandigarh, India
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.590
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHS58
引用
收藏
页码：A502 / A503
页数：2
相关论文
共 24 条
  • [1] Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
    Ahn, D.
    Park, N. J.
    Locker, M. C.
    Zhou, Z-Y.
    Nie, X.
    Wang, T.
    Yu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S613 - S613
  • [2] Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety
    Merle, Philippe
    Kudo, Masatoshi
    Krotneva, Stanimira
    Ozgurdal, Kirhan
    Su, Yun
    Proskorovsky, Irina
    LIVER CANCER, 2023, 12 (02) : 145 - 155
  • [3] Network meta-analysis (NMA) and matching-adjusted indirect comparison (MAIC) of pembrolizumab versus atezolizumab for second-line (2L) locally advanced/metastatic urothelial carcinoma (mUC)
    Gelb, Dave
    Zhong, Yichen
    Perini, Rodolfo Fleury
    Godwin, James Luke
    Lai, Yizhen
    Arndorfer, Stella
    Lorenzi, Maria
    Li, Haojie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis
    Andrea Casadei-Gardini
    Lorenza Rimassa
    Margherita Rimini
    Changhoon Yoo
    Baek-Yeol Ryoo
    Sara Lonardi
    Gianluca Masi
    Hyung-Don Kim
    Caterina Vivaldi
    Min-Hee Ryu
    Mario Domenico Rizzato
    Francesca Salani
    Yeonghak Bang
    Antonio Pellino
    Silvia Catanese
    Valentina Burgio
    Stefano Cascinu
    Alessandro Cucchetti
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 3665 - 3671
  • [5] Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: Matching-adjusted indirect comparison analysis
    Gardini, A. Casadei
    Rimassa, L.
    Yoo, C.
    Lonardi, S.
    Cucchetti, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S105 - S105
  • [6] Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis
    Casadei-Gardini, Andrea
    Rimassa, Lorenza
    Rimini, Margherita
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Lonardi, Sara
    Masi, Gianluca
    Kim, Hyung-Don
    Vivaldi, Caterina
    Ryu, Min-Hee
    Rizzato, Mario Domenico
    Salani, Francesca
    Bang, Yeonghak
    Pellino, Antonio
    Catanese, Silvia
    Burgio, Valentina
    Cascinu, Stefano
    Cucchetti, Alessandro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (12) : 3665 - 3671
  • [7] SAFETY PROFILE AND MANAGEMENT OF SELECT TREATMENT-RELATED ADVERSE EVENTS IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) TREATED WITH NIVOLUMAB IN THE CHECKMATE-040 STUDY
    Galway, Aralee
    DiFebo, Holly
    Brutcher, Edith
    Julien, Karen
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [8] Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison
    Porta, Camillo
    Szczylik, Cezary
    Casciano, Roman
    Fu, Shuai
    Amzal, Billy
    Lister, Johanna
    Karcher, Helene
    Meng, Jie
    Neumann, Monika
    Dinet, Jerome
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 139 : 143 - 148
  • [9] Comparison of clinical outcome between Nivolumab and Regorafenib as second-line systemic therapy after Sorafenib failure in patients with advanced hepatocellular carcinoma
    Lee, Jae Seung
    Lee, Hong Jun
    Lee, Hye Won
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Jun Yong
    Ahn, Sang Hoon
    Kim, Do Young
    JOURNAL OF HEPATOLOGY, 2023, 78 : S595 - S595
  • [10] Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis
    Rizzo, Alessandro
    Carloni, Riccardo
    Ricci, Angela Dalia
    Cusmai, Antonio
    Laforgia, Mariarita
    Calabro, Concetta
    Ungaro, Valentina
    Oreste, Donato
    Sollitto, Mario
    Palmiotti, Gennaro
    Brandi, Giovanni
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (04) : 323 - 329
123